Betagistin

General characteristics. Structure:

Active ingredient: 8 mg, 16 mg or 24 mg of a betagistin of dihydrochloride.

Pharmacological properties:

Pharmacodynamics. Antagonist histamine H1 receptors of vessels of an inner ear and antagonist histamine H3 receptors of vestibular nuclei of TsNS. Due to relaxation of precapillary sphincters of vessels of an inner ear improves blood circulation in a vascular stripe of an inner ear. Dozozavisimo reduces generation of action potentials in neurons of lateral and medial vestibular nuclei. Accelerates recovery of vestibular function after a unilateral vestibular neurectomy, accelerating and facilitating the central vestibular compensation (due to antagonism with histamine H3 receptors). Facilitates symptomatology at Menyer's syndrome and vestibular dizziness. The stable therapeutic effect occurs in 14 days.

Pharmacokinetics. Linkng with proteins of plasma — low, less than 5% is absorbed quickly. Cmax in a blood plasma is reached in 1 h. It is metabolized to inactive metabolites: 2-pyridylacetic acid (main metabolite) and demetilbetagistina. Almost completely (to 85-90%) it is brought by kidneys in the form of a metabolite (2-pyridylacetic acid) during 24 h. Removal of a betagistin and demetilbetagistin kidneys slightly. Intestines remove only a small part of a betagistin and its metabolites.

Indications to use:

— the treatment of a syndrome of Menyer who is characterized by dizziness (which is followed by nausea and vomiting), decrease in hearing and a sonitus;

— symptomatic treatment of vestibular dizziness (вертиго).

Route of administration and doses:

Inside, during food.

Tablets of 8 mg: on 1-2 таб. 3 times/days.

Tablets of 16 mg: 1/2 таб. 3 times/days.

Tablets of 24 mg: on 1 таб. 2 times/days.

The course of treatment is defined individually. Improvement is usually noted already at the beginning of therapy, stable the therapeutic effect occurs after two weeks of treatment and can increase within several months of treatment. Prolonged treatment. Duration of administration of drug is selected individually.

Features of use:

Use at pregnancy and feeding by a breast. Drug is contraindicated to use at pregnancy as also the fruit there are not enough data for assessment of impact of drug on pregnant women. In the period of a lactation drug should not be used or for the period of treatment it is necessary to stop breastfeeding.

Use for children. It is contraindicated aged up to 18 years (efficiency and safety are not established);

Special instructions. The therapeutic effect in some cases increases within several months from an initiation of treatment.

Influence on ability to driving of motor transport and to control of mechanisms. Betagistin does not possess sedation and does not influence ability to drive the car or to work at machines and mechanisms.

Side effects:

Frequency: often — more than 1/100 and less than 1/10.

From the alimentary system: often — nausea, dyspepsia.

Post-marketing experience. Allergic reactions: hypersensitivity (including anaphylactic reactions, Quincke's disease, skin rash, small tortoiseshell, Quincke's edema).

From the alimentary system: vomiting, abdominal pain, abdominal distention.

From integuments: itch.

Interaction with other medicines:

Cases of interaction or incompatibility with other drugs are unknown.

Contraindications:

— children up to 18 years (due to the lack of data);

— pregnancy;

— lactation period;

— hypersensitivity to one of drug components.

With care: a peptic ulcer of a stomach or duodenum (in the anamnesis), a pheochromocytoma, bronchial asthma.

Overdose:

Symptoms: nausea, vomiting, abdominal pain, drowsiness (at reception in a dose to 640 mg); spasms, cardiopulmonary complications (at reception in a dose more than 640 mg or in combination with other medicines).

Treatment: gastric lavage, reception of absorbent carbon, symptomatic therapy.

Storage conditions:

To store drug in the dry, protected from light place at a temperature not above 25 °C. To store in the place, unavailable to children. A period of validity - 2 years.

Not to use after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

On 30 tablets in strip packagings and cardboard packs.